Xin Lang Ji Jin·2026-03-03 07:12Group 1 - The core point of the news is that Tigermed has experienced a decline in stock price, dropping 3.33% to 56.88 CNY per share, with a total market capitalization of 48.975 billion CNY and a cumulative drop of 7.17% over the past four days [1] - Tigermed is a clinical research service provider established in December 2004, specializing in I-IV phase clinical trials, data management, regulatory submissions, and other related services [1] - The company's revenue composition includes 52.60% from clinical trial-related services, 45.21% from clinical trial technical services, and 2.19% from other services [1] Group 2 - The fund "Shangyin High-Quality Preferred 9-Month Holding Period Mixed A" holds 69,700 shares of Tigermed, representing 5.56% of the fund's net value, making it the third-largest holding [2] - The fund has incurred a floating loss of approximately 136,600 CNY today and a total floating loss of 306,000 CNY during the four-day decline [2] - The fund was established on November 3, 2021, with a current scale of 64.8908 million CNY, and has a year-to-date return of 1.14% [2]